It was reported that mTOR is activated in cyst-lining cells in human ADPKD kidneys and inhibition of mTOR pathway reverses renal cystogenesis in animal models [20], although clinical trials with rapamycin in human ADPKD patients were disappointing [21]. Here, MTOR is linked to autosomal dominant polycystic kidney disease.